Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm vNKT cell immunotherapy in advanced hepatocellular carcinoma after progression following second-line therapy
ChiCTR2300078114Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Dec 2023
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vNKT cellular immunotherapy in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: overall survival, objective response rate and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
vNKT cellular immunotherapy
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300078114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078114.